Biogen’s New Alzheimer’s Trial Results Spark Value‑Based Reimbursement and Market Expansion
Biogen’s Phase‑2/3 data show sustained 5‑year benefits for lecanemab and a 2‑year slowdown with diranersen, boosting its AD pipeline’s value‑based revenue prospects.
4 minutes to read


